{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:30:56Z","timestamp":1789979456647,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["EMA\/2015\/25\/PH"],"award-info":[{"award-number":["EMA\/2015\/25\/PH"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To study patterns of antiepileptic drugs (AED) prescribing, particularly valproate, during pregnancy over a 10\u2010year period in the UK, Italy, and France.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data on pregnancies conceived after 1 January 2007 with outcomes before 31 December 2016 were extracted from four European electronic health care databases (380 499 in the United Kingdom (UK), 66 681 in France, and 649 918 in Italy [355 767 in Emilia Romagna and 294 151 in Tuscany]). Prevalence of AEDs with an ATC code starting N03A and clobazam (N05BA09) were stratified by country and calendar year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AED prescribing during pregnancy varied from 3.0 (2.8\u20103.1) per 1000 pregnancies in Emilia Romagna to 7.8 (7.5\u20108.0) in the UK, 5.9 (5.6\u20106.1) in Tuscany, and 6.3 (5.7\u20106.9) in France. Lamotrigine was commonly prescribed in all regions with a third of women exposed to an AED during pregnancy taking lamotrigine in the UK and France. Valproate was prescribed to 28.6% of AED exposed pregnant women in Tuscany, 21.6% in France, 16.7% in Emilia Romagna, and 11.9% in the UK. Over the study period, the prevalence of AED prescribing increased in the UK mainly due to increases in pregabalin and gabapentin, declined in France mainly related to decreases in clonazepam, and remained constant in Italy. Valproate prescriptions declined to a prevalence &lt;1 per 1000 pregnancies in 2015 to 2016 in the UK, France, and Emilia Romagna.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Variations in AED prescribing during pregnancy indicate the potential for further reductions, particularly of valproate. Increases in pregabalin\/gabapentin prescribing, for which risks are not well known, are a cause for concern.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4897","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T10:05:42Z","timestamp":1568369142000},"page":"1510-1518","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7651-9130","authenticated-orcid":false,"given":"Caroline","family":"Hurault\u2010Delarue","sequence":"first","affiliation":[{"name":"Pharmacologie Facult\u00e9 de M\u00e9decine Universit\u00e9 Paul\u2010Sabatier Toulouse III CHU Toulouse, UMR INSERM  Toulouse 1027 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-612X","authenticated-orcid":false,"given":"Joan K.","family":"Morris","sequence":"additional","affiliation":[{"name":"Population Health Research Institute St George's, University of London St George's, University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Charlton","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[{"name":"Agenzia Regionale di Sanit\u00e0 della Toscana  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Loane","sequence":"additional","affiliation":[{"name":"Centre for Maternal, Fetal and Infant Research, INHR Ulster University  Newtowanbbey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierini","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology\u2014National Research Council (IFC\u2010CNR)\/Fondazione Toscana \u201cGabriele Monasterio\u201d  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Puccini","sequence":"additional","affiliation":[{"name":"Drug Policy Service Emilia Romagna Region Health Authority  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Neville","sequence":"additional","affiliation":[{"name":"IMER (Emilia Romagna Registry of Birth Defects) Centre for Clinical and Epidemiological Research University of Ferrara and Azienda Ospedaliero\u2010Universitaria di Ferrara  Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Snowball","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damase\u2010Michel","sequence":"additional","affiliation":[{"name":"Pharmacologie Facult\u00e9 de M\u00e9decine Universit\u00e9 Paul\u2010Sabatier Toulouse III CHU Toulouse, UMR INSERM  Toulouse 1027 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EUROmediSAFE consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"CharltonR Damase\u2010MichelD\u2010M Hurault\u2010DelarueC et al.Prescriptions of antiepileptic medications in women in three European countries between 2007 and 2016: effect of a warning concerning valproate.2018."},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.074203"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.04.022"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13632"},{"issue":"11","key":"e_1_2_14_6_1","first-page":"CD010224","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","author":"Weston J","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14485"},{"issue":"10","key":"e_1_2_14_8_1","first-page":"CD010236","article-title":"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child","author":"Bromley R","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2009.04.026"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01376.x"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2270"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2005.tb01190.x"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2013.08.001"},{"key":"e_1_2_14_15_1","unstructured":"PRAC recommends strengthening the restrictions on the use of valproate in women and girls\u2014WC500175208.pdf [Internet]. [cit\u00e9 2018]. Disponible sur:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2014\/10\/WC500175208.pdf"},{"key":"e_1_2_14_16_1","unstructured":"Medicines related to valproate: risk of abnormal pregnancy outcomes [Internet]. GOV.UK. [cit\u00e9 2018]. Disponible sur:https:\/\/www.gov.uk\/drug\u2010safety\u2010update\/medicines\u2010related\u2010to\u2010valproate\u2010risk\u2010of\u2010abnormal\u2010pregnancy\u2010outcomes"},{"key":"e_1_2_14_17_1","unstructured":"Valproate et d\u00e9riv\u00e9s (D\u00e9pakine\u00ae D\u00e9pakote\u00ae D\u00e9pamide\u00ae Micropakine\u00ae et g\u00e9n\u00e9riques) : risque d'issues anormales de grossesse\u2014Lettre aux professionnels de sant\u00e9\u2014ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 [Internet]. [cit\u00e9 2018]. Disponible sur:http:\/\/ansm.sante.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Valproate\u2010et\u2010derives\u2010Depakine\u2010R\u2010Depakote\u2010R\u2010Depamide\u2010R\u2010Micropakine\u2010R\u2010et\u2010generiques\u2010risque\u2010d\u2010issues\u2010anormales\u2010de\u2010grossesse\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante"},{"key":"e_1_2_14_18_1","unstructured":"Valproate et d\u00e9riv\u00e9s: contre\u2010indication pendant la grossesse (sauf situations exceptionnelles) et programme de pr\u00e9vention des grossesses\u2014Lettre aux professionnels de sant\u00e9\u2014ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 [Internet]. [cit\u00e9 2018]. Disponible sur:https:\/\/ansm.sante.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Valproate\u2010et\u2010derives\u2010contre\u2010indication\u2010pendant\u2010la\u2010grossesse\u2010sauf\u2010situations\u2010exceptionnelles\u2010et\u2010programme\u2010de\u2010prevention\u2010des\u2010grossesses\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante"},{"key":"e_1_2_14_19_1","unstructured":"Prescribing information on valproic acid\u2014Black box (FDA) [Internet]. [cit\u00e9 2019]. Disponible sur:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/018081s069 018082s052lbl.pdf"},{"key":"e_1_2_14_20_1","unstructured":"FDA Drug Safety Communication: valproate anti\u2010seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. FDA[Internet]; Available on:http:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010valproate\u2010anti\u2010seizure\u2010products\u2010contraindicated\u2010migraine\u2010prevention"},{"key":"e_1_2_14_21_1","unstructured":"FDA Drug Safety Communication: valproate information. FDA[Internet]; available on:http:\/\/www.fda.gov\/drugs\/postmarket\u2010drug\u2010safety\u2010information\u2010patients\u2010and\u2010providers\/valproate\u2010information"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3613"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3847"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052339"},{"key":"e_1_2_14_25_1","unstructured":"Exposition in utero \u00e0 l'acide valpro\u00efque et aux autres traitements de l'\u00e9pilepsie et des troubles bipolaires et risque de malformations cong\u00e9nitales majeures (MCM) en France\u2014fb3faa8c4a5c5c5dedfc1423213c219d.pdf [Internet]. [cit\u00e9 2018]. Disponible sur:http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/fb3faa8c4a5c5c5dedfc1423213c219d.pdf"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ppe.12004"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-016-0078-1"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002767"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003959"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0920-4"},{"key":"e_1_2_14_31_1","unstructured":"Pregabalin and gabapentin: advice for prescribers on the risk of misuse [Internet]. GOV.UK. [cit\u00e9 2018]. Disponible sur:https:\/\/www.gov.uk\/government\/publications\/pregabalin\u2010and\u2010gabapentin\u2010advice\u2010for\u2010prescribers\u2010on\u2010the\u2010risk\u2010of\u2010misuse"},{"key":"e_1_2_14_32_1","unstructured":"Rivotril (clonaz\u00e9pam) : Modification des conditions de prescription et de d\u00e9livrance\u2014Lettre aux professionnels de sant\u00e9\u2014Actualis\u00e9 le 04\/01\/2012\u2014ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 [Internet]. [cit\u00e9 2018]. Disponible sur: http:\/\/ansm.sante.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Rivotril\u2010clonazepam\u2010Modification\u2010des\u2010conditions\u2010de\u2010prescription\u2010et\u2010de\u2010delivrance\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante\u2010Actualise\u2010le\u201004\u201001\u20102012"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01186.x"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.01.019"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.144386"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01260.x"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606133342407"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb06037.x"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000304343.45104.d6"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0433-0"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.2.321"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103073241006"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198906223202505"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4897","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:44:26Z","timestamp":1694169866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/pds.4897"],"URL":"https:\/\/doi.org\/10.1002\/pds.4897","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"2019-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}